US4908213A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Transdermal delivery of nicotine
Assignee: Merck Sharp & Dohme LLC
•
Filing: 1989-02-21
•
Granted: 1990-03-13
•
Expires: 2009-02-21
Abstract
Abstract A transdermal nicotine patch comprising an antipruritic to counteract pruritis observed with the transdermal administration of nicotine is disclosed. The patch can be any conventional patch type, e.g., reservoir, adhesive or polymeric matrix.
Inventors
- 👤 Sharad K. Govil
- 👤 Paul Kohlman
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-01 16:22
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/70; A61K9/7023; A61K31/00; A61K31/33; A61K31/395; A61K31/435; A61K31/465
Claims Analysis
Total Claims: 15
Claim 1
Independent Claim
59 words
An adhesive, polymeric matrix or reservoir transdermal delivery patch for the controlled release of nicotine comprising an amount of nicotine or a pharmaceutically acceptable salt or solvate thereof effective to treat symptoms associated with tobacco smoking cessation and an amount of an antipruritic effective to treat the pruritis associated with transdermal delivery of nicotine, in a pharmaceutically acceptable carrier.
Claim 2
Dependent Claim
59 words
An adhesive, polymeric matrix or reservoir transdermal delivery patch for the controlled release of nicotine comprising an amount of nicotine or a pharmaceutically acceptable salt or solvate thereof effective to treat symptoms associated with tobacco smoking cessation and an amount of an antipruritic effective to treat the pruritis associated with transdermal delivery of nicotine, in a pharmaceutically acceptable carrier.
Claim 3
Dependent Claim
33 words
A transdermal patch of claim 1 wherein the salts and solvates of nicotine are selected from the group consisting of the hydrochloride, dihydrochloride, sulfate, tartrate, bitartarate, zinc chloride double salt monohydrate and salicylate.
Claim 4
Dependent Claim
33 words
A transdermal patch of claim 1 wherein the nicotine or salt or solvate thereof comprises 5 to 40% of the total weight of the nicotine or salt or solvate thereof, antipruritic and carrier.
Claim 5
Dependent Claim
10 words
A transdermal patch of claim 3 comprising nicotine free base.
Claim 6
Dependent Claim
28 words
A transdermal patch of claim 4 wherein the antipruritic is selected from the group consisting of bisabolol, oil of chamomile, chamazulene, allantoin, D-panthenol, glycyrrhetenic acid, corticosteroids and antihistamines.
Claim 7
Dependent Claim
11 words
A transdermal patch of claim 5 wherein the antipruritic is bisabolol.
Claim 8
Dependent Claim
11 words
A transdermal patch of claim 6 wherein the antipruritic is α(-)bisabolol.
Claim 9
Dependent Claim
30 words
A transdermal patch of claim 7 wherein the α(-)bisabolol comprises about 0.1 to about 2% of the total weight of the nicotine or salt or solvate thereof, α(-)bisabolol and carrier.
Claim 10
Dependent Claim
16 words
A transdermal patch of claim 8 wherein the carrier comprises a pharmaceutically acceptable pressure sensitive adhesive.
Claim 11
Dependent Claim
21 words
A transdermal patch of claim 9 wherein the adhesive is selected from the group consisting of acrylic, silicone and polyisobutylene adhesive.
Claim 12
Dependent Claim
14 words
A transdermal patch of claim 8 wherein the carrier comprises a polymeric-matrix forming agent.
Claim 13
Dependent Claim
30 words
A method for treating the symptoms associated with tobacco smoking cessation comprising applying a transdermal patch of claim 8 to the skin of a human in need of such treatment.
Claim 14
Dependent Claim
35 words
An adhesive transdermal patch of claim 1 comprising 20% nicotine free base and 1% α(-)bisabolol, and wherein the carrier comprises 71.5% acrylic pressure sensitive adhesive, 4% water, 2.5% butylated hydroxyanisole and 1% acrylic polymer thickener.
Claim 15
Dependent Claim
30 words
A method for treating the symptoms associated with tobacco smoking cessation comprising applying a transdermal patch of claim 1 to the skin of a human in need of such treatment.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1993-03-12 | 1993-09-11 | 1994-03-13 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1997-03-12 | 1997-09-11 | 1998-03-13 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2001-03-12 | 2001-09-11 | 2002-03-13 | $7700.00 | Window Closed / Lapsed |